SG11202011201QA - Fully human antibodies against ox40, method for preparing same, and use thereof - Google Patents

Fully human antibodies against ox40, method for preparing same, and use thereof

Info

Publication number
SG11202011201QA
SG11202011201QA SG11202011201QA SG11202011201QA SG11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA
Authority
SG
Singapore
Prior art keywords
human antibodies
antibodies against
fully human
preparing same
preparing
Prior art date
Application number
SG11202011201QA
Inventor
Yong Zheng
Baotian Yang
Jing Li
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd, Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of SG11202011201QA publication Critical patent/SG11202011201QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202011201QA 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof SG11202011201QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018086574 2018-05-11
CN201810529840 2018-05-29
PCT/CN2019/085886 WO2019214624A1 (en) 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof

Publications (1)

Publication Number Publication Date
SG11202011201QA true SG11202011201QA (en) 2020-12-30

Family

ID=68466901

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011201QA SG11202011201QA (en) 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof

Country Status (11)

Country Link
US (1) US20210171647A1 (en)
EP (2) EP3790903A4 (en)
JP (1) JP7411575B2 (en)
KR (1) KR20210039986A (en)
CN (2) CN110467674B (en)
AU (1) AU2019264712A1 (en)
BR (1) BR112020023026A2 (en)
CA (1) CA3103040A1 (en)
MX (1) MX2020012081A (en)
SG (1) SG11202011201QA (en)
WO (1) WO2019214624A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021098769A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
CN113045655A (en) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof
CN113045654A (en) * 2019-12-27 2021-06-29 南开大学 anti-OX 40 antibodies and uses thereof
US20230139700A1 (en) * 2020-03-23 2023-05-04 Bio-Thera Solutions, Ltd. Development and application of immune cell activator
CN117003868B (en) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN111518209B (en) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 Monoclonal antibodies that specifically bind to human OX40 and uses thereof
TW202229352A (en) * 2020-11-12 2022-08-01 大陸商同潤生物醫藥(上海)有限公司 Combination therapy and methods utilizing the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
DE60317677T2 (en) * 2002-06-13 2008-10-30 Crucell Holland B.V. OX40 (= CD134) RECEPTOR AGONISTS AND THERAPEUTIC USES
TWI461436B (en) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
CN101918447B (en) 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 Binding molecules to the human OX40 receptor
NZ629913A (en) * 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
LT2731677T (en) * 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2931030B2 (en) 2012-12-14 2024-01-17 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
RS57840B1 (en) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
RU2675516C2 (en) * 2013-08-02 2018-12-19 Пфайзер Инк. Anti-cxcr4 antibodies and antibody-drug conjugates
EP3632934A1 (en) 2014-03-31 2020-04-08 F. Hoffmann-La Roche AG Anti-ox40 antibodies and methods of use
TW201619200A (en) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
SG11201708804WA (en) * 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
WO2016185016A1 (en) 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
CA2987410A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CN108137684B (en) * 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 anti-OX40 antibodies and uses thereof
MA43389A (en) * 2015-12-02 2021-05-12 Agenus Inc ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN107815465B (en) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model

Also Published As

Publication number Publication date
EP4074732A1 (en) 2022-10-19
JP2021522847A (en) 2021-09-02
JP7411575B2 (en) 2024-01-11
BR112020023026A2 (en) 2021-02-09
TW202003575A (en) 2020-01-16
KR20210039986A (en) 2021-04-12
AU2019264712A1 (en) 2021-01-07
CN110467674A (en) 2019-11-19
EP3790903A1 (en) 2021-03-17
EP3790903A4 (en) 2022-06-08
MX2020012081A (en) 2021-04-28
WO2019214624A1 (en) 2019-11-14
CN110467674B (en) 2022-05-31
CA3103040A1 (en) 2019-11-14
US20210171647A1 (en) 2021-06-10
CN114685665A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
SG11202003782XA (en) Triple-chain antibody, method for preparation and use thereof
SG11202011201QA (en) Fully human antibodies against ox40, method for preparing same, and use thereof
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
EP3664762A4 (en) Surgical frame including torso-sling and method for use thereof
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
PT3546457T (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
SG11202009962UA (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
EP3708582A4 (en) 4-1bb antibody and preparation method and use thereof
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
EP3632907C0 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
HK1258545A1 (en) Urea compound, preparation method therefor and medical use thereof
IL272446A (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
EP3632932A4 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
HK1258007A1 (en) Human programmed cell death 1 receptor antibody, method of preparing same, and use thereof
EP3589670A4 (en) Elastomer, method for preparation thereof, and use thereof
EP3822290A4 (en) Sema4d antibody, preparation method therefor and use thereof
EP3395834A4 (en) Tpbg antibody and preparation method therefor, conjugate and use thereof
ZA201908091B (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
EP3773720A4 (en) A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
EP3730620A4 (en) Cross-immunizing antigen vaccine and method for preparation thereof
GB202008327D0 (en) Method for preparing 2,2'dipyridine and derivatives thereof
RS61158B1 (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof
GB201904104D0 (en) Composition, method and use
EP3589350A4 (en) Medical device, method for preparation thereof, and use thereof
EP3758751A4 (en) Monoclonal antibody against human lag-3, method for preparing same, and use thereof